SCHEMBL18227271

SCHEMBL18227271

[N-]=[N+]=NC[C@H](O)c1cc(OCc2ccccc2)cc2c1OCC(=O)N2

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 19/20 0.49
ADRB1 P08588 12/20 0.47
CHRM2 P08172 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
HTR2A P28223 1/20 0.41
SLC6A4 P31645 1/20 0.41
ADRA1A P35348 1/20 0.41
PTGS2 P35354 1/20 0.41
HTR2B P41595 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PDE4D Q08499 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12594506 0.85 ADRB2 (0.54) ADRB2ADRB1
SCHEMBL561768 0.84 ADRB2 (0.53) ADRB2ADRB1
SCHEMBL20321903 0.84 ADRB2 (0.54) ADRB2ADRB1CHRM2HTR1AADRA2A
SCHEMBL18239919 0.83 ADRB2 (0.43) ADRB2ADRB1CHRM2HTR1AADRA2A
SCHEMBL19350700 0.81 ADRB2 (0.62) ADRB2ADRB1
SCHEMBL13494723 0.80 ADRB1 (0.46) ADRB2ADRB1
SCHEMBL18227270 0.80 MAOA (0.41) ADRB2ADRB1
SCHEMBL28171184 0.80 MAOA (0.34) ADRB2
SCHEMBL17481985 0.78 ADRB2 (0.39) ADRB2ADRB1
SCHEMBL1856496 0.77 ADRB2 (0.47) ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108502-A having beta2Biphenyl derivatives with receptor agonism and M receptor antagonistic activity and application thereof in medicine 四川海思科制药有限公司 2017-08-29 CN disclosed
WO-2016180349-A1 BIPHENYL DERIVATIVE HAVING BETA2 RECEPTOR EXCITEMENT AND M RECEPTOR ANTAGONISTIC ACTIVITIES AND APPLICATION THEREFOF IN MEDICAMENT 四川海思科制药有限公司 2016-11-17 WO disclosed